Organogenesis (ORGO) to Release Earnings on Thursday

Organogenesis (NASDAQ:ORGO) will post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Organogenesis to post earnings of ($0.03) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Organogenesis Stock Performance

Organogenesis stock opened at $2.39 on Tuesday. Organogenesis has a 1 year low of $1.96 and a 1 year high of $4.70. The company has a market cap of $315.38 million, a PE ratio of 59.76 and a beta of 1.60. The company has a current ratio of 2.80, a quick ratio of 2.44 and a debt-to-equity ratio of 0.22. The company’s 50-day moving average is $2.82 and its two-hundred day moving average is $3.09.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $5.00 target price on shares of Organogenesis in a research report on Friday, March 1st.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.